Royal Bank Of Canada Kodiak Sciences Inc. Transaction History

Royal Bank Of Canada

$425 Billion
Q2 2024

A detailed history of Royal Bank Of Canada transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 3,188 shares of KOD stock, worth $8,480. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,188

Previous 4,416 27.81%

Holding current value

$8,480

Previous $23,000 69.57%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.29 - $4.48 $2,812 - $5,501	-1,228 Reduced 27.81%	3,188 $7,000
Q1 2024 May 15, 2024	SELL	$3.01 - $7.45 $18,854 - $46,666	-6,264 Reduced 58.65%	4,416 $23,000
Q4 2023 Feb 14, 2024	BUY	$1.4 - $3.24 $4,517 - $10,455	3,227 Added 43.3%	10,680 $32,000
Q3 2023 Nov 14, 2023	BUY	$1.8 - $7.49 $7,110 - $29,585	3,950 Added 112.76%	7,453 $13,000
Q2 2023 Aug 14, 2023	BUY	$4.3 - $9.48 $6,346 - $13,992	1,476 Added 72.82%	3,503 $24,000
Q1 2023 May 15, 2023	SELL	$4.81 - $8.88 $90,413 - $166,917	-18,797 Reduced 90.27%	2,027 $12,000
Q4 2022 Feb 14, 2023	BUY	$6.52 - $8.05 $86,272 - $106,517	13,232 Added 174.29%	20,824 $149,000
Q3 2022 Nov 14, 2022	BUY	$7.57 - $12.5 $27,062 - $44,687	3,575 Added 89.0%	7,592 $59,000
Q2 2022 Aug 15, 2022	SELL	$5.04 - $9.48 $8,779 - $16,514	-1,742 Reduced 30.25%	4,017 $31,000
Q1 2022 May 16, 2022	SELL	$7.09 - $89.45 $41,901 - $528,649	-5,910 Reduced 50.65%	5,759 $45,000
Q4 2021 Feb 14, 2022	BUY	$80.85 - $128.49 $352,829 - $560,730	4,364 Added 59.74%	11,669 $990,000
Q3 2021 Nov 15, 2021	SELL	$81.97 - $106.94 $980,033 - $1.28 Million	-11,956 Reduced 62.07%	7,305 $701,000
Q2 2021 Aug 16, 2021	BUY	$77.2 - $126.54 $1.49 Million - $2.44 Million	19,261 New	19,261 $1.79 Million

Others Institutions Holding KOD

# of Institutions

104

Shares Held

39.8M

Call Options Held

7.6K

Put Options Held

3.5K

View Full List

About Kodiak Sciences Inc.

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $138M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

More about KOD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Kodiak Sciences Inc. Transaction History